Medical Director Articles

The term "article" is used to describe any bulletin article, web site article, educational handout or any other non-LCD document intended for public release that contains coverage/coding statements or medical review related billing or claims considerations.

Articles address local coverage, coding or medical review related billing and claims considerations, and may include any newly developed educational materials, coding instructions or clarification of existing medical review related billing or claims policy.

The article listing will continue to expand as additions are made.

Last Updated Jan 30 , 2024
Articles Source Posted
Billing and Coding: High Compression Bandage System Clarification (A53287) Retirement - Effective July 19, 2023 Jul 27, 2023
MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease (L36180) - R12 - Effective July 06, 2023 Jul 07, 2023
Billing and Coding: MolDX: Repeat Germline Testing (A57331) - R7 - Effective July 01, 2023 Jul 07, 2023
Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454) - R4 - Effective July 06, 2023 Jul 07, 2023
Billing and Coding: MolDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer (A57664) - R2 - Effective July 01, 2023 Jul 07, 2023
Billing and Coding: MolDX: Germline Testing for use of PARP inhibitors (A55294) - R10 - Effective July 28, 2022 Jul 07, 2023
Billing and Coding: Immune Globulin Intravenous (IVIg) (A57187) - R7 - Effective July 1, 2023 Jul 06, 2023
Self-Administered Drug Exclusion List: (A53032) - R30 - Effective August 20, 2023 Jul 06, 2023
Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58720) - R9 - Effective July 1, 2023 Jul 06, 2023
Billing and Coding: MolDX: Molecular Diagnostic Tests (MDT) (A57526) - R13 - Effective July 1, 2023 Jul 06, 2023
Billing and Coding: MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer (A58181) Final Billing and Coding Article - Effective August 06, 2023 Jun 30, 2023
MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer L38647 Final LCD - Effective August 06, 2023 Jun 30, 2023
Billing and Coding: MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma (A59179) Final Billing and Coding Article - Effective August 06, 2023 Jun 30, 2023
MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma L39373 Final LCD - Effective August 06, 2023 Jun 30, 2023
Billing and Coding: Implantable Infusion Pumps for Chronic Pain (A55239) - R13 - Effective July 1, 2023 Jun 29, 2023
MolDX: Envisia, Veracyte, Idiopathic Pulmonary Fibrosis Diagnostic Test (L37887) - R6 - Effective June 29, 2023 Jun 29, 2023
Billing and Coding: IUD (Hormone-Eluting) for Endometrial Hyperplasia - CPT 58999 (A55061) - R3 - Effective October 15, 2015 Jun 29, 2023
Billing and Coding: Lab: Controlled Substance Monitoring and Drugs of Abuse Testing (A55001) - R17 - Effective July 1, 2023 Jun 29, 2023
Billing and Coding: MolDX: Abbott RealTime IDH1 and IDH2 testing for Acute Myeloid Leukemia (AML) (A55711) - R5 - Effective June 01, 2023 Jun 29, 2023
Billing and Coding: Sacroiliac Joint Injections and Procedures (A59244) - R1 - Effective March 19, 2023 Jun 22, 2023